- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06831162
Evaluación de la efectividad de una iniciativa de necesidades sociales relacionadas con la salud de varios niveles
The goal of this study is to evaluate the effectiveness of a multi-level health-related social needs (HRSN) initiative among adult patients diagnosed with type 2 diabetes, plus hypertension or hyperlipidemia. The multi-level initiative includes HRSN data collection, training and tools for health care professionals, care coordinator support, and community resources. Patients with type 2 diabetes plus hypertension or hyperlipidemia will be screened for HRSN as part of the primary care clinic intake process to assess if patients have any social needs (like difficulty with getting food, housing, or transportation). If patients screen positive for having social needs, then patients will be offered support, which can include help from primary care providers with adjusting a patient's disease management plan, referrals to care coordinators to provide additional assistance in addressing social needs, and information about community organizations that offer resources for social needs. The initiative will be integrated as a system change across VUMC adult primary care practices.
The investigators will use a prospective, single-arm clinical trial to evaluate effects on clinical outcomes for 12 months. Data will be extracted from the EHR on adult patients diagnosed with type 2 diabetes, and either hypertension or hyperlipidemia. The investigators hypothesize that the initiative will reduce the impact of HRSN on clinical outcomes over the study period. The investigators will also administer surveys to a subgroup of patients to examine trends in self-reported psychosocial and behavioral measures over the course of the initiative.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Vanderbilt University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
ELIGIBILITY CRITERIA FOR EHR DATA EXTRACTION
Inclusion Criteria:
- 18 years of age or older
- Completed the health-related social needs (HRSN) screener as part of a primary care visit
- Diagnosed with type 2 diabetes, plus hypertension and/or hyperlipidemia as reflected by ICD-10 billing codes
- Receive care at one of six partner Vanderbilt University Medical Center primary care clinics: South One Hundred Oaks, North One Hundred Oaks, Green Hills, Hillsboro Medical Group, Melrose, Bellevue
ELIGIBILITY CRITERIA FOR PATIENT SURVEYS (subset of EHR data)
Inclusion Criteria:
- 18 years of age or older
- Completed the HRSN screener as part of a primary care visit
- Diagnosed with type 2 diabetes
- Receive care at one of six partner Vanderbilt University Medical Center primary care clinics: South One Hundred Oaks, North One Hundred Oaks, Green Hills, Hillsboro Medical Group, Melrose, Bellevue
- English-speaking
Exclusion Criteria:
- Blindness
- Hearing impairment
- Conditions that would interfere with survey completion (e.g., significant dementia, active psychosis or mania)
- Being near the end of life (hospice or home hospice)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Multi-level HRSN initiative
Eligible patients will receive the HRSN initiative as part of their primary care appointments |
The multi-level health-related social needs (HRSN) initiative includes multiple components aimed at assessing and addressing HRSN in clinical practice: HRSN screening, EHR tools for clinical decision support, training and tools for health care providers to address HRSN, care coordinator support for patient outreach, and community resources for referral and support. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in glycemic control
Periodo de tiempo: Baseline and 12 months post-baseline
|
Hemoglobin A1c extracted from the electronic health record where higher values indicate worse glycemic control. |
Baseline and 12 months post-baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in cholesterol
Periodo de tiempo: Baseline and 12 months post-baseline
|
Low-density lipoprotein (LDL) extracted from the electronic health record where higher values indicate worse hyperlipidemia. |
Baseline and 12 months post-baseline
|
|
Change in blood pressure
Periodo de tiempo: Baseline and 12 months post-baseline
|
Systolic blood pressure extracted from the EHR where higher values indicate worse hypertension. |
Baseline and 12 months post-baseline
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in medication adherence (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the Adherence to Refills and Medications Scale-Diabetes (ARMS-D) with scores ranging from 11-44, where higher scores indicate more problems with medication adherence (worse). |
Baseline and 6 months post-baseline
|
|
Change in dietary behavior (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the short version of the Personal Diabetes Questionnaire scale (PDQ-11) Eating Behavior Problems subscale with scores ranging 1-6, where higher scores indicate more problem eating behaviors (worse). |
Baseline and 6 months post-baseline
|
|
Change in dietary behavior (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the short version of the Personal Diabetes Questionnaire scale (PDQ-11) Use of Information for Decision Making subscale with scores ranging 1-6, where higher scores indicate more use of dietary information for decision making (better). |
Baseline and 6 months post-baseline
|
|
Change in physical activity (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by scores on the Exercise Vital Sign (EVS) Tool with scores ranging 0-1,050 minutes or greater per week of moderate to strenuous physical activity. |
Baseline and 6 months post-baseline
|
|
Change in diabetes distress (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the Problem Areas in Diabetes-5 (PAID-5) scale with scores ranging from 0 to 20, where higher scores indicate greater diabetes-related emotional distress (worse). |
Baseline and 6 months post-baseline
|
|
Change in diabetes self-efficacy (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the Perceived Diabetes Self-Management Scale (PDSMS) with scores ranging 8 to 40, where higher scores indicate more self-efficacy (better). |
Baseline and 6 months post-baseline
|
|
Change in interpersonal processes of care (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed by the Interpersonal Processes of Care (IPC) survey with scores ranging from 1-5 (calculated as the mean of non-missing responses to the corresponding items), where higher scores indicate higher frequency of the labeled interpersonal process (e.g., decided together; lack of clarity). Scoring occurs for 7 interpersonal processes: lack of clarity; elicited concerns, responded; explained results; decided together; emotional support, compassion; discriminated due to race/ethnicity; and disrespectful office staff. |
Baseline and 6 months post-baseline
|
|
Change in perceived discrimination (survey)
Periodo de tiempo: Baseline and 6 months post-baseline
|
As assessed on the Discrimination in Medical Settings scale with scores ranging from 7-35, where higher scores indicate higher frequency of experiences with discrimination in medical settings. |
Baseline and 6 months post-baseline
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sunil Kripalani, MD, MSc, Vanderbilt University Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Dislipidemias
- Trastornos del metabolismo de los lípidos
- Enfermedades Nutricionales y Metabólicas
- Hipertensión
- Diabetes Mellitus, Tipo 2
- Hiperlipidemias
Otros números de identificación del estudio
- 241778
- P50MD017347-03S3 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.
Marco de tiempo para compartir IPD
After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later
Criterios de acceso compartido de IPD
Contact the principal investigator
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .